Latest Breaking News On - Genentech avastin - Page 1 : comparemela.com

Pearce IP BioBlast w/e 22 March 2024

On 22 March 2024, the first case management hearing was held before Justice Nicholas in the Federal Court of Australia, Sydney, in proceedings…

Pearce IP BioBlast w/e 26 Jan 2024

AbbVie announced it will invest US$233M in its biologics manufacturing facility in Singapore. The investment will add 24,000L of biologics…

FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP

On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis.

AstraZeneca's Imfinzi combination shows promise in phase 3 liver cancer study

AstraZeneca/Merck's Lynparza recommended by NICE for advanced prostate cancer